CymaBay Therapeutics
CBAY
$32.48
Share price
0.00%
Change (1 day)
221.27%
Change (1 year)
Categories
Operating Margin for CymaBay Therapeutics (CBAY)
Operating Margin at the end of 2017: -264.77%
According to CymaBay Therapeutics 's latest financial reports and stock price the company's current Operating Margin is -264.77%. At the end of 2017 the company had an Operating Margin of -264.77%.
Operating Margin history for CymaBay Therapeutics from 2012 to 2017
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2017 | -264.77% | |
| 2012 | -341.44% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 34.61% | -113.07% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 19.24% | -107.27% | 🇺🇸 USA |
 Xencor XNCR | -141.63% | -46.51% | 🇺🇸 USA |
 PTC Therapeutics
PTCT | -84.20% | -68.20% | 🇺🇸 USA |
What is a company's Operating Margin
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.